drugset
drugset / Trial / NCT03172910

Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT

NCT03172910 ↗

Phase 2 Completed 69 enrolled AMAG Pharmaceuticals, Inc.
RandomizedSequentialSingle-blindTreatment

Summary

This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and safety of ciraparantag administered to healthy volunteers anticoagulated with rivaroxaban measuring clotting times using Whole Blood Clotting Time (WBCT).

Timeline

Start
2017-05-08
Primary completion
2019-11-12
Completion
2019-11-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ciraparantag Small molecule 30 mg Intravenous
Subject Ciraparantag Small molecule 60 mg Intravenous
Subject Ciraparantag Small molecule 120 mg Intravenous
Subject Ciraparantag Small molecule 180 mg Intravenous
Background Rivaroxaban Other / unclassified 20 mg —

Indications

No indication recorded.